105 related articles for article (PubMed ID: 31876381)
1. Development of an in vitro screening assay for PIP5K1α lipid kinase and identification of potent inhibitors.
Strätker K; Haidar S; Amesty Á; El-Awaad E; Götz C; Estévez-Braun A; Jose J
FEBS J; 2020 Jul; 287(14):3042-3064. PubMed ID: 31876381
[TBL] [Abstract][Full Text] [Related]
2. Autodisplay of human PIP5K1α lipid kinase on Escherichia coli and inhibitor testing.
Strätker K; Haidar S; Dubiel M; Estévez-Braun A; Jose J
Enzyme Microb Technol; 2021 Feb; 143():109717. PubMed ID: 33375977
[TBL] [Abstract][Full Text] [Related]
3. 1,2,3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors.
Haidar S; Amesty Á; Oramas-Royo S; Götz C; El-Awaad E; Kaiser J; Bödecker S; Arnold A; Aichele D; Amaro-Luis JM; Estévez-Braun A; Jose J
Bioorg Med Chem; 2024 May; 105():117727. PubMed ID: 38669736
[TBL] [Abstract][Full Text] [Related]
4. The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.
Semenas J; Hedblom A; Miftakhova RR; Sarwar M; Larsson R; Shcherbina L; Johansson ME; Härkönen P; Sterner O; Persson JL
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):E3689-98. PubMed ID: 25071204
[TBL] [Abstract][Full Text] [Related]
5. Development of a High-Throughput Screening Assay to Identify Inhibitors of the Lipid Kinase PIP5K1C.
Wright BD; Simpson C; Stashko M; Kireev D; Hull-Ryde EA; Zylka MJ; Janzen WP
J Biomol Screen; 2015 Jun; 20(5):655-62. PubMed ID: 25534829
[TBL] [Abstract][Full Text] [Related]
6. The role of PIP5K1α/pAKT and targeted inhibition of growth of subtypes of breast cancer using PIP5K1α inhibitor.
Sarwar M; Syed Khaja AS; Aleskandarany M; Karlsson R; Althobiti M; Ødum N; Mongan NP; Dizeyi N; Johnson H; Green AR; Ellis IO; Rakha EA; Persson JL
Oncogene; 2019 Jan; 38(3):375-389. PubMed ID: 30104711
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Structure-Activity Relationship Study of (
Manz TD; Sivakumaren SC; Ferguson FM; Zhang T; Yasgar A; Seo HS; Ficarro SB; Card JD; Shim H; Miduturu CV; Simeonov A; Shen M; Marto JA; Dhe-Paganon S; Hall MD; Cantley LC; Gray NS
J Med Chem; 2020 May; 63(9):4880-4895. PubMed ID: 32298120
[TBL] [Abstract][Full Text] [Related]
8. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
9. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002).
Vlahos CJ; Matter WF; Hui KY; Brown RF
J Biol Chem; 1994 Feb; 269(7):5241-8. PubMed ID: 8106507
[TBL] [Abstract][Full Text] [Related]
10. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
[TBL] [Abstract][Full Text] [Related]
11. TF--a novel cell-permeable and selective inhibitor of human protein kinase CK2 induces apoptosis in the prostate cancer cell line LNCaP.
Götz C; Gratz A; Kucklaender U; Jose J
Biochim Biophys Acta; 2012 Jul; 1820(7):970-7. PubMed ID: 22387500
[TBL] [Abstract][Full Text] [Related]
12. Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer.
Carabet LA; Lallous N; Leblanc E; Ban F; Morin H; Lawn S; Ghaidi F; Lee J; Mills IG; Gleave ME; Rennie PS; Cherkasov A
Eur J Med Chem; 2018 Dec; 160():108-119. PubMed ID: 30326371
[TBL] [Abstract][Full Text] [Related]
13. Ethyl 2-(benzylidene)-7-methyl-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-6-carboxylate analogues as a new scaffold for protein kinase casein kinase 2 inhibitor.
Jin CH; Jun KY; Lee E; Kim S; Kwon Y; Kim K; Na Y
Bioorg Med Chem; 2014 Sep; 22(17):4553-65. PubMed ID: 25131958
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.
Wortmann L; Bräuer N; Holton SJ; Irlbacher H; Weiske J; Lechner C; Meier R; Karén J; Siöberg CB; Pütter V; Christ CD; Ter Laak A; Lienau P; Lesche R; Nicke B; Cheung SH; Bauser M; Haegebarth A; von Nussbaum F; Mumberg D; Lemos C
J Med Chem; 2021 Nov; 64(21):15883-15911. PubMed ID: 34699202
[TBL] [Abstract][Full Text] [Related]
15. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth.
Deng R; Yang F; Chang SH; Tang J; Qin J; Feng GK; Ding K; Zhu XF
Mol Pharmacol; 2012 Aug; 82(2):189-98. PubMed ID: 22553359
[TBL] [Abstract][Full Text] [Related]
16. PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells.
Li J; Gao Z; Zhao D; Zhang L; Qiao X; Zhao Y; Ding H; Zhang P; Lu J; Liu J; Jiang H; Luo C; Chen C
Cancer Res; 2017 Nov; 77(22):6253-6266. PubMed ID: 28827373
[TBL] [Abstract][Full Text] [Related]
17. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
[TBL] [Abstract][Full Text] [Related]
18. A high-throughput screen reveals new small-molecule activators and inhibitors of pantothenate kinases.
Sharma LK; Leonardi R; Lin W; Boyd VA; Goktug A; Shelat AA; Chen T; Jackowski S; Rock CO
J Med Chem; 2015 Feb; 58(3):1563-8. PubMed ID: 25569308
[TBL] [Abstract][Full Text] [Related]
19. A High-Throughput Genetic Complementation Assay in Yeast Cells Identified Selective Inhibitors of Sphingosine Kinase 1 Not Found Using a Cell-Free Enzyme Assay.
Kashem MA; Kennedy CA; Fogarty KE; Dimock JR; Zhang Y; Sanville-Ross ML; Skow DJ; Brunette SR; Swantek JL; Hummel HS; Swindle J; Nelson RM
Assay Drug Dev Technol; 2016; 14(1):39-49. PubMed ID: 26426296
[TBL] [Abstract][Full Text] [Related]
20. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.
Jung ME; Byun BJ; Kim HM; Lee JY; Park JH; Lee N; Son YH; Choi SU; Yang KM; Kim SJ; Lee K; Kim YC; Choi G
Bioorg Med Chem Lett; 2016 Jun; 26(11):2719-23. PubMed ID: 27106709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
